SF 0166

Drug Profile

SF 0166

Alternative Names: SF0166

Latest Information Update: 05 Oct 2016

Price : $50

At a glance

  • Originator SciFluor Life Sciences
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

  • 30 Sep 2016 Phase-I/II clinical trials in Age-related macular degeneration in USA (Ophthalmic) (NCT02914639)
  • 30 Sep 2016 Phase-I/II clinical trials in Diabetic macular oedema in USA (Ophthalmic) (NCT02914613)
  • 01 Aug 2016 US FDA approves IND application for SF 0166 in Age-related macular degeneration and Diabetic macular oedema
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top